TRCT
RANI icon

Tower Research Capital (TRC)’s Rani Therapeutics RANI Stock Holding History

Tower Research Capital (TRC)’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.05K Buy
12,318
+4,633
+60% +$5.92K ﹤0.01% 3942
2025
Q4 		$10.4K Buy
7,685
+1,461
+23% +$2.2K ﹤0.01% 3785
2025
Q3 		$3.11K Sell
6,224
-3,061
-33% -$1.59K ﹤0.01% 4544
2025
Q2 		$4.77K Buy
+9,285
New +$7.58K ﹤0.01% 4270
2024
Q4 		– Sell
-1,721
Closed -$3.72K – 5943
2024
Q3 		$3.72K Sell
1,721
-12,716
-88% -$36.4K ﹤0.01% 4788
2024
Q2 		$54.9K Buy
14,437
+13,198
+1,065% +$68.4K ﹤0.01% 3030
2024
Q1 		$3.85K Sell
1,239
-1,069
-46% -$3.68K ﹤0.01% 4780
2023
Q4 		$7.66K Buy
+2,308
New +$5.34K ﹤0.01% 4593
2023
Q3 		– Sell
-7,048
Closed -$29K – 6180
2023
Q2 		$29K Buy
7,048
+3,211
+84% +$14.9K ﹤0.01% 3051
2023
Q1 		$20K Buy
3,837
+1,330
+53% +$8K ﹤0.01% 3440
2022
Q4 		$15K Buy
2,507
+1,129
+82% +$8.23K ﹤0.01% 3446
2022
Q3 		$13K Sell
1,378
-205
-13% -$2.17K ﹤0.01% 4285
2022
Q2 		$16K Buy
1,583
+1,045
+194% +$12K ﹤0.01% 4021
2022
Q1 		$7K Sell
538
-2,108
-80% -$35K ﹤0.01% 4753
2021
Q4 		$43K Buy
+2,646
New +$60.1K ﹤0.01% 2887

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Tower Research Capital (TRC)'s RANI Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Rani Therapeutics (RANI) stake by 60% in Q1 2026, buying an estimated $5.92K and bringing the position to 12,318 shares worth $9.05K. The position accounts for ﹤0.01% of the portfolio, ranked #3942.

Tower Research Capital (TRC) first reported a position in RANI in Q4 2021 and has held it in 15 quarters since. The position peaked at $54.9K in Q2 2024. 74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

  • Tower Research Capital (TRC) held 12,318 shares of Rani Therapeutics worth $9.05K as of Q1 2026.
  • Tower Research Capital (TRC) bought 4,633 Rani Therapeutics shares in Q1 2026, an estimated $5.92K.
  • Rani Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3942 holding.
  • Tower Research Capital (TRC) first reported a position in Rani Therapeutics in Q4 2021 and has held it in 15 quarters since.
  • Tower Research Capital (TRC)'s Rani Therapeutics position peaked at $54.9K in Q2 2024.
  • 74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.